Literature DB >> 23469320

Priapism lasting 19 hours with combined use of trazodone and mirtazapine in a patient with history of successfully tolerating each agent as monotherapy.

Taral R Sharma1.   

Abstract

Entities:  

Year:  2012        PMID： 23469320      PMCID： PMC3583761          DOI： 10.4088/PCC.12l01349

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN： 2155-7780


× No keyword cloud information.
  10 in total

1.  American Urological Association guideline on the management of priapism.

Authors:  Drogo K Montague; Jonathan Jarow; Gregory A Broderick; Roger R Dmochowski; Jeremy P W Heaton; Tom F Lue; Ajay Nehra; Ira D Sharlip
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

2.  Penile amputation after trazodone-induced priapism: a case report.

Authors:  Paul Hoffmann; E Tull Neu; Daniel Neu
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

3.  Treatment of intermittent idiopathic priapism with oral terbutaline.

Authors:  I Ahmed; N A Shaikh
Journal:  Br J Urol       Date:  1997-08

4.  Priapism as a probable sequel to medication.

Authors:  S O Rubin
Journal:  Scand J Urol Nephrol       Date:  1968

5.  Risperidone-induced priapism.

Authors:  M K Ankem; V J Ferlise; K R Han; M A Gazi; A R Koppisch; R E Weiss
Journal:  Scand J Urol Nephrol       Date:  2002-02

6.  Chart for preparation of dilutions of alpha-adrenergic agonists for intracavernous use in treatment of priapism.

Authors:  M Lee; B Cannon; R Sharifi
Journal:  J Urol       Date:  1995-04       Impact factor: 7.450

7.  Oral terbutaline for the treatment of priapism.

Authors:  F E Govier; E Jonsson; D Kramer-Levien
Journal:  J Urol       Date:  1994-04       Impact factor: 7.450

8.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

9.  Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism.

Authors:  R Berger; K Billups; G Brock; G A Broderick; C B Dhabuwala; I Goldstein; L S Hakim; W Hellstrom; S Honig; L A Levine; T Lue; R Munarriz; D K Montague; J J Mulcahy; A Nehra; Z R Rogers; R Rosen; A D Seftel; R Shabsigh; W Steers
Journal:  Int J Impot Res       Date:  2001-12       Impact factor: 2.896

10.  Incidence of priapism in the general population.

Authors:  I A Eland; J van der Lei; B H Stricker; M J Sturkenboom
Journal:  Urology       Date:  2001-05       Impact factor: 2.649
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.